Editas Medicine shares have underperformed the S&P 500 by over 108% in the last three years. The company has a promising pipeline and is making strides in preclinical and clinical trials. However, ...

Thinking about CRISPR Therapeutics and wondering if now is your chance to scoop up value, or if the stock is already priced in with the excitement? Let's break down what the numbers and news say about ...

If you've ever thought about investing in the gene-editing biotech space, Editas Medicine (NASDAQ: EDIT) and CRISPR Therapeutics (NASDAQ: CRSP) are doubtlessly familiar to you. While neither company ...

In our modern age, the power of gene editing is undeniable. After years of foundational scientific research, it's now becoming possible to treat illnesses that were until very recently intractable.

We recently published a list of 10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Editas Medicine, Inc. (NASDAQ:EDIT) stands ...

Korro Bio stock plummeted Thursday after its RNA-editing drug failed to pass muster in patients with a rare lung and liver ...

Over the next year, a series of clinical milestones and regulatory decisions—what companies and investors like to call “inflection points”—will set for years to come the direction of what has been ...

Caribou Biosciences has plenty of money for the next year or so, and great data. Editas Medicine is far behind the competition with its lead programs. Editas will probably struggle to get funding for ...